Physician profile
Michael Johnson
NPI 1821197476
$4,615.07
in general payments reported to CMS, 2019-2025
26 companies · $633 in 2025
The $633 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $134 · 2021: $119 · 2022: $718 · 2023: $2,391 · 2024: $261 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,280 · Education: $1,148 · Travel and Lodging: $857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,280.47 |
| Education | $1,147.98 |
| Travel and Lodging | $857.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,006.95 | 2022-2023 | Davinci Xi, Da Vinci Sp, Da Vinci Surgical System |
| Abbvie INC. | $464.96 | 2019-2025 | |
| Hologic Sales and Service, LLC | $416.98 | 2019-2025 | Acessa Provu System, Sonata Sonography-Guided Transcervical Fibroid Ablation System, Aptima |
| Astellas Pharma US INC | $405.63 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $356.50 | 2019-2025 | |
| Coopersurgical, INC. | $354.80 | 2019-2024 | Advincula Delineator Uterine Manipulator, Summit Doppler, Endosee |
| Sage Therapeutics, LLC | $67.26 | 2025 | Zurzuvae |
| Organon LLC | $64.09 | 2021-2024 | |
| Pfizer INC. | $46.33 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $45.67 | 2025 | |
| Coloplast Corp | $43.87 | 2022-2023 | Altis |
| Exeltis, USA INC. | $42.50 | 2020 | |
| Lilly USA, LLC | $40.29 | 2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $40.13 | 2023-2024 | Wegovy |
| Sumitomo Pharma America, INC. | $33.68 | 2025 | Myfembree |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $25.17 | 2025 | Truclear |
| Daiichi Sankyo INC. | $23.67 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $22.32 | 2024 | Bd Onclarity |
| Minerva Surgical, INC | $16.74 | 2025 | |
| Glaxosmithkline, LLC. | $16.51 | 2019 | |
| Therapeuticsmd, INC. | $15.62 | 2022 | |
| Lupin INC. | $15.11 | 2020 | |
| Allergan, INC. | $14.50 | 2020 | |
| Vertical Pharmaceuticals, LLC | $12.24 | 2019 | |
| Dysis Medical, INC. | $12.02 | 2021 | |
| Amag Pharmaceuticals, INC. | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.